Akèy › Maladi Crohn › Connecticut
Etid klinik pou Maladi Crohn nan Connecticut
14 etid pou Maladi Crohn ap chèche patisipan nan sit nan Connecticut.
Vil nan Connecticut
Tèks ofisyèl etid la (Anglè)
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- Connecticut Clinical Research Institute ( Site 0297), Bristol
Ap rekriteFaz 3
Tout laj · Tout sèks · Mizajou Oct 2, 2026 · NCT06651281A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Yale University School of Medicine-Digestive Disease ( Site 5019), New Haven
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Oct 2, 2026 · NCT06430801Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Danbury Hospital, Western Connecticut Health Network /ID# 265556, Danbury
- Yale University School of Medicine /ID# 266786, New Haven
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT06548542A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Medical Research Center of Connecticut, Hamden
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07499232Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Smilow Cancer Center/Yale-New Haven Hospital, New Haven
- Yale University, New Haven
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT03816345An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Yale University Digestive Disease-Site Number: 8400108, New Haven
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Sep 23, 2026 · NCT07184931A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
- Connecticut Children's Medical Center, Hartford
Ap rekriteFaz 3
Laj 2 a 19 · Tout sèks · Mizajou Sep 22, 2026 · NCT04844606A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- Medical Research Center of Connecticut, LLC, Hamden
Ap rekriteFaz 4
Laj 18 a 70 · Tout sèks · Mizajou Sep 9, 2026 · NCT06045754A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Connecticut Children's Medical Center, Hartford
Ap rekriteFaz 3
Laj 2 a 17 · Tout sèks · Mizajou Aug 24, 2026 · NCT05509777Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
- Yale University, New Haven
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT05230173Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- Yale University School of Medicine, New Haven
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT07237516Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD
- Connecticut Children's Medical Center, Hartford
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 10 a 21 · Tout sèks · Mizajou Jul 16, 2026 · NCT07224113Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- Connecticut Children's Medical Center - Hartford /ID# 262256, Hartford
Ap rekriteFaz 3
Laj 2 a 17 · Tout sèks · Mizajou Jun 24, 2026 · NCT06332534Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Connecticut Children's Medical Center, Hartford
Ap rekriteFaz 4
Laj 6 a 17 · Tout sèks · Mizajou May 27, 2026 · NCT05781152Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.